NKTX Stock Summary and Trading Ideas (Nkarta | NASDAQ:NKTX)

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Nkarta trades on the NASDAQ stock market under the symbol NKTX.

As of July 22, 2026, NKTX stock price declined to $2.41 with 720,114 million shares trading.

NKTX has a beta of 3.27, meaning it tends to be more sensitive to market movements. NKTX has a correlation of 0.21 to the broad based SPY ETF.

NKTX has a market cap of $172.42 million. This is considered a Micro Cap stock.

In the last 3 years, NKTX traded as high as $16.24 and as low as $1.28.

The top ETF exchange traded funds that NKTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

NKTX has outperformed the market in the last year with a return of +25.5%, while the SPY ETF gained +20.1%. However, in the most recent history, NKTX shares have underperformed the stock market with its stock returning -27.4% in the last 3 month period and -28.7% for the last 2 week period, while SPY has returned +6.4% and 0.0%, respectively.

NKTX support price is $2.42 and resistance is $2.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTX shares will trade within this expected range on the day.